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Expression of either Epstein-Barr virus (EBV) immediate-early protein BZLF1 (Z) or BRLF1 (R) is
sufficient to convert EBV infection from the latent to lytic form. Disruption of viral latency requires transcrip-
tional activation of the Z and R promoters. The Z and R proteins are transcriptional activators, and each
immediate-early protein activates expression of the other immediate-early protein. Z activates the R promoter
through a direct binding mechanism. However, R does not bind directly to the Z promoter. In this study, we
demonstrate that the ZII element (a cyclic AMP response element site) in the Z promoter is required for
efficient activation by R. The ZII element has been shown to be important for induction of lytic EBV infection
by tetradecanoyl phorbol acetate and surface immunoglobulin cross-linking and is activated by Z through an
indirect mechanism. We demonstrate that both R and Z activate the cellular stress mitogen-activated protein
(MAP) kinases, p38 and JNK, resulting in phosphorylation (and activation) of the cellular transcription factor
ATF2. Furthermore, we show that the ability of R to induce lytic EBV infection in latently infected cells is
significantly reduced by inhibition of either the p38 kinase or JNK pathways. In contrast, inhibition of stress
MAP kinase pathways does not impair the ability of Z expression vectors to disrupt viral latency, presumably
because expression of Z under the control of a strong heterologous promoter bypasses the need to activate Z
transcription. Thus, both R and Z can activate the Z promoter indirectly by inducing ATF2 phosphorylation,
and this activity appears to be important for R-induced disruption of viral latency.
Epstein-Barr virus (EBV) is a member of the human her-
pesvirus family of viruses and is the causative agent of infec-
tious mononucleosis (61). EBV has also been found in associ-
ation with a variety of cancers, including Burkitt’s lymphoma
and nasopharyngeal carcinoma (61, 82). Upon primary infec-
tion, EBV infects epithelial cells, where it undergoes lytic rep-
lication, and B cells, where it usually remains latent (37, 45, 61,
67). However, in a small percentage of B cells, latent EBV can
become reactivated and undergo lytic replication. This viral
reactivation is initiated by the two EBV immediate-early pro-
teins, BZLF1 and BRLF1 (5, 8, 36, 57, 62, 63, 69, 77, 80).
The BZLF1 (Z) and BRLF1 (R) proteins function as tran-
scriptional activators of the EBV early genes (9, 20, 28–30, 35,
46, 56, 74), and the expression of either Z or R is sufficient to
induce lytic replication in both latently infected epithelial cells
and B cells (5, 8, 57, 69, 77, 80). Regardless of which immedi-
ate-early gene is initially transcribed, expression of one imme-
diate-early protein leads to the expression of the other (80),
and full activation of early genes requires the presence of both
immediate-early proteins (1, 80). Z activates the R promoter
by directly binding to Z-response elements (ZREs) (1, 66).
However, the mechanism by which R activates Z expression
remains unknown. Although the R protein binds directly to a
GC-rich motif present in enhancer elements upstream of sev-
eral EBV early promoters (24, 25, 56), there are no known R
binding sites within the Z promoter (25). Thus, R could po-
tentially activate the Z promoter through an indirect mecha-
nism involving modulation of a cellular transcription factor.
The ZII element in the Z promoter functions as an impor-
tant positive regulator of Z transcription (16). ZII is required
for both efficient tetradecanoyl phorbol acetate induction of Z
transcription (16) and activation induced by surface immuno-
globulin (Ig) cross-linking (10). In addition, human herpesvirus
6 (HHV-6) infection has been shown to activate the Z pro-
moter through this site (14). Mutant forms of Z unable to bind
DNA have also been shown to activate transcription depen-
dent upon the ZII element (15), although the exact mechanism
for this effect remains unknown. Previous reports, as well as
data from our own laboratory, have shown that the cellular
factors binding to the ZII element include CREB, ATF1,
ATF2, and c-Jun (49, 76). Of these proteins, CREB and ATF1
have been reported to activate the Z promoter in reporter gene
assays (49, 76).
CREB, ATF1, and ATF2 are all members of the CREB/
ATF family of transcription factors that bind directly to DNA
via cyclic AMP-response elements (CREs), and each of these
proteins requires phosphorylation in order to function effi-
ciently as transcriptional activators (22, 26, 51, 58, 60, 75).
Activation of the CREB and ATF1 proteins occurs primarily
through phosphorylation by protein kinase A (PKA) (22, 60),
whereas ATF2 is activated after phosphorylation by either the
p38 or c-Jun–N-terminal (JNK) stress kinases (26, 58, 75).
JNK-mediated phosphorylation is also required for activation
of the c-Jun transcription factor (11, 42), which can het-
erodimerize with ATF2 (27). Thus, activation of Z transcrip-
tion through the ZII element could potentially be mediated
through phosphorylation of the CRE family and/or c-Jun tran-
scription factors.
* Corresponding author. Mailing address: Lineberger Comprehen-
sive Cancer Center, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599-7295. Phone: (919) 966-1248. Fax: (919) 966-
8212. E-mail: shann@med.unc.edu.
1224
Here we have studied the effects of R and Z expression upon
the cellular transcription factors binding to the ZII motif. We
demonstrate that although neither R nor Z expression signif-
icantly affects the levels of CREB, ATF1, ATF2, or c-Jun
binding to ZII, R and Z both induce phosphorylation of p38
kinase as well as JNK. Furthermore, we find that the ability of
R to disrupt viral latency efficiently requires activation of the
stress mitogen-activated protein (MAP) kinase cascade. These
results suggest that a key initial step in the disruption of viral
latency by R is the activation of JNK and p38 kinase, thereby
allowing R to induce Z transcription through phosphorylation
of the ATF2 and c-Jun transcription factors.
MATERIALS AND METHODS
Cell lines. DG75 is an EBV-negative Burkitt’s lymphoma cell line. Akata (68)
and Raji are EBV-positive Burkitt’s lymphoma cell lines. B95-8 is an EBV-
positive marmoset B-cell line. HeLa is a cervical carcinoma cell line. NIH 3T3 is
a mouse fibroblast cell line. NPC-KT is an EBV-positive epithelial cell line
derived from the fusion of a human adenoidal epithelial cell line and a primary
EBV-positive nasopharyngeal carcinoma (70). D98/HE-R-1 is an epithelial cell
line formed by fusion of a HeLa cell subclone (D98) with the EBV-positive
Burkitt’s lymphoma cell line P3HR/1 (21). All lymphoid cell lines were main-
tained in RPMI 1640 medium supplemented with 10% fetal calf serum. Epithe-
lial cell lines were maintained in Dulbecco’s modified Eagle’s medium H sup-
plemented with 10% fetal calf serum.
Adenovirus construction and infection. The BZLF1 and BRLF1 cDNAs were
cloned into a shuttle vector (under the control of the cytomegalovirus [CMV]
promoter) which contains a Lox P site, the left adenovirus terminal repeat, and
a packaging signal. These vectors were recombined (in a cell line expressing the
phage P1 Cre protein) into the Lox P site of an adenovirus lacking the E1 and E3
genes, to create adenovirus-Z and adenovirus-R, as previously described (77). A
control vector (adenovirus-LacZ) containing the lacZ gene was made in the same
manner.
HeLa cells were plated at a cell density of 3 3 106 cells per 140 by 20 mm plate.
Cells were infected with no adenovirus (mock), adenovirus-LacZ, adenovirus-Z,
or adenovirus-R at a multiplicity of infection of 50. The cells were harvested 24
to 48 h postinfection.
Plasmids. EApBS-CAT contains the early EBV BMRF1 promoter sequences
from 2331 to 11 linked to the chloramphenicol acetyltransferase (CAT) gene
(56). Gal4-E1b-CAT (gift of Michael Green) contains five copies of the Gal4
DNA binding site upstream of the E1B minimal TATA element and the CAT
gene (47). ZpBS-CAT contains the immediate-early EBV BZLF1 promoter
sequences from 2552 to 112 linked to the CAT gene (1). 2221 Zp-CAT
contains the immediate-early EBV BZLF1 promoter sequences from 2221 to
112 linked to the CAT gene, while 2221 ZpZIIm-CAT contains a mutated ZII
element (AAACGAATTCATCACAGAG) (16) (gifts of Erik Flemington).
The R expression vector (RTS15) contains the R genomic sequence under the
control of the simian virus 40 early promoter (a gift from Diane Hayward). The
wild-type Z expression vector contains the BZLF1 cDNA, downstream of the
CMV immediate-early promoter, in the pHD1013 vector (56). The ZDLZ vector
has a deletion of the Z leucine zipper from amino acid 196 to amino acid 228.
The Z311 vector contains a mutation in the DNA binding domain of Z in which
amino acid 185 is altered (abolishing DNA binding) (20, 34). Z-CT (previously
referred to as RAZDR), has a deletion of Z amino acids 2 to 86 (a gift of Joseph
Pagano) (18). The SG424 vector contains the GAL4 DNA binding domain alone
(amino acids 1 to 147), whereas the Gal4-CREB, GAL4-ATF1, and GAL4-ATF2
constructs contain the indicated cDNAs linked in frame to GAL4 (gifts of
Michael Green) (39, 64). GAL4–c-Jun contains the c-Jun cDNA fused to the
Gal4 DNA binding domain in the SG424 vector (a gift of Al Baldwin). RSV
(Rous sarcoma virus)-ATF2 contains the ATF2 cDNA in the RSV-pECE vector,
and RSV-ATF1 contains the ATF1 cDNA in the RSV-pECE vector (gifts of
Michael Green) (48). RSV-CREB contains the CREB cDNA (gift of Michael
Green) (22). CMV-p38 contains the human p38 cDNA (a gift of Roger Davis) in
the pcDNA3 vector. CMV-JNK contains the JNK cDNA in the pcDNA3B
vector, and CMV-cdc42 contains the cdc42QL cDNA in the pcDNA3B vector
(gifts from Lynn Vitale Cross). The PKA expression vector contains the catalytic
subunit of PKA (mouse), under the mouse metallothionein 1 promoter (gift from
Stanley McKnight) (73). Dominant-negative MKK3 contains a mutation at
amino acid 193 of threonine to alanine, under the RSV promoter, in the pRc/
RSV vector, and dominant-negative MKK6 contains a mutation at amino acid 82
FIG. 1. R activates the Z promoter through the ZII element. DG75 or Raji
cells were transfected with 5 mg of promoter construct (2221 Zp-CAT or 2221
ZpZIIm-CAT) and 1 mg of vector control DNA or R expression plasmid. CAT
assays were performed. The fold activation, relative to vector alone, is shown.
Error bars indicate range.
FIG. 2. ATF1, ATF2, CREB, and c-Jun bind to the ZII element of the Z promoter. EMSAs were performed with a 32P-labeled ZII probe and B95-8 protein extracts.
(Left panel) Twenty micrograms of protein extract was incubated in the absence (lane 2) or presence of a CRE consensus DNA competitor (lane 3) or an Sp1 consensus
DNA competitor (lane 4); in the presence of antibodies directed against ATF1 (lane 5), ATF2 (lane 6), c-Jun (lane 7), or ATF2 plus c-Jun (lane 8); or a control antibody
(lane 9). (Right panel) Twenty micrograms of protein extract was incubated in the absence (lane 1) or presence of antibodies directed against CREB (lane 2) or a control
antibody (lane 3). A and B indicate the two pertinent complexes. The antibodies alone did not induce supershifts in the absence of cellular extract (data not shown).
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of lysine to alanine, under the CMV promoter, in the pcDNA3 vector (59). GST
(glutathione S-transferase)–c-Jun contains the first 79 amino acids of c-Jun
linked to GST (a gift from Shelley Earp). The JIP-1 expression vector (12) is a
gift from Roger Davis.
DNA purification. Plasmid DNA was purified through QIAGEN columns as
described by the manufacturer.
DNA transfection. DNA (5 to 10 mg) was transfected into cells by electropo-
ration with a Zapper electroporation unit (Medical Electronics Shop, University
of Wisconsin) at 1,500 V as described previously (71). All cells were resuspended
in RPMI 1640 medium prior to electroporation.
NIH 3T3 cells were transfected with Lipofectamine (Gibco BRL) as per the
manufacturer’s instructions.
CAT assays. Cell extracts were prepared 48 h posttransfection and incubated
at 37°C with [14C]chloramphenicol in the presence of acetyl coenzyme A as
described previously (23). The percent acetylation of chloramphenicol was quan-
titated by thin-layer chromatography followed by PhosphorImager screening
(Molecular Dynamics).
Immunoblot analysis. Immunoblot analysis was performed for the detection of
total ATF-2, CREB, p38, MKK3, MKK6, BMRF1, Z, and R proteins as follows.
Briefly, 10 to 100 mg of protein was loaded in each lane, and sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed. The
proteins were transferred overnight onto nitrocellulose (Protran), blocked in 13
phosphate-buffered saline (PBS)–5% milk–0.1% Tween 20, and incubated in
primary antibody for 1 h at room temperature (ATF2 and CREB [1:500] from
Santa Cruz, p38 [1:1,000] from New England Biolabs, MKK3 and MKK6
[1:1,000] from New England Biolabs, BMRF1 [1:100] from Capricorn, anti-EBV
ZEBRA [1:100] from Argene or Z125 [1:50], from Alain Sergeant, and R [1:100]
from Argene). The membrane was washed in PBS–0.1% Tween 20, incubated in
secondary antibody for 1 h at room temperature {goat anti-mouse-kappa con-
jugated with horseradish peroxidase (GAM-kappa–HRP [1:2,000]) from South-
ern Biotechnology, goat anti-rabbit–HRP [1:10,000] from Promega} and washed,
and the results were visualized with the ECL enhanced chemiluminescence kit
(Amersham) according to the manufacturer’s instructions.
The detection of phosphorylated ATF2, CREB/ATF1, p38, MKK3, and
MKK6 proteins differed as follows: membranes were blocked in 13 Tris-buffered
saline (TBS)–0.1% Tween 20–5% milk and washed with TBST (13 TBS–0.1%
Tween 20). The primary antibody was diluted in 13 TBS–0.1% Tween 20–5%
bovine serum albumin (BSA) and was incubated overnight at 4°C (phospho-
ATF2, phospho-CREB/ATF1, phospho-MKK3, phospho-MKK6, and phospho-
p38 [1:1,000] from New England Biolabs). The secondary antibody was diluted in
blocking solution and was incubated for 1 h at room temperature.
Protein preparation. B95-8 cells were washed twice with PBS, resuspended in
200 ml of extraction buffer (50 mM HEPES [pH 7], 250 mM NaCl, 0.1% NP-40,
5 mM EDTA, 5 mM dithiothreitol [DTT], protease inhibitors), freeze-thawed
twice, and centrifuged. The supernatant was used for electrophoretic mobility
shift assays (EMSAs).
Adenovirus-infected HeLa cells were resuspended in low-salt buffer (150 mM
NaCl, 20 mM Tris [pH 7.5], 5 mM EDTA, 1% Triton X-100, 50 mM NaF, 10%
glycerol, 1 mM NaVO4, protease inhibitors). Cell lysates were tumbled for 15
min at 4°C and centrifuged. The supernatant was used for Western blots.
Transfected or adenovirus-infected NPC-KT cells or D98/HE-R-1 cells were
resuspended in 50 ml of buffer (0.25 M NaCl, 0.1% NP-40, 0.05 M HEPES [pH
7], 5 mM EDTA, protease inhibitors), freeze-thawed twice, and centrifuged. The
supernatant was used for Western blots.
Cells treated with the p38 kinase inhibitor SB 202190 (Calbiochem) were
incubated in medium containing a final concentration of 10 mM inhibitor for
24 h.
GST–c-Jun was induced, and cells were sonicated and centrifuged. The super-
natant was incubated with glutathione-agarose beads for 30 min at room tem-
perature, and the beads were washed three times with PBS.
Kinase assays. HeLa cells were infected with adenovirus-LacZ, adenovirus-Z,
or adenovirus-R for 24 h, washed twice with PBS, and lysed in 0.9 ml of low-salt
buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 5 mM EDTA, 1% Triton X-100, 50
mM NaF, 10% glycerol, 1 mM NaVO4, protease inhibitors). Cell lysates were
tumbled for 15 min at 4°C and centrifuged. One hundred fifty micrograms of
protein was incubated with GST–c-Jun–beads, tumbled for 2 h at 4°C, and
centrifuged. The beads were washed three times with low-salt buffer and then
washed one time with kinase buffer (73 buffer 5 140 mM HEPES [pH 7.5], 70
mM MgCl2, 350 mM NaCl, 7 mM DTT, 35 mM B-glycerophosphate, 10.5 mM
EGTA). The beads were incubated in 35 ml of reaction mix (per reaction, 5 ml of
73 kinase buffer, 10 mM ATP, 1 ml of [g-32P]ATP, distilled water to 35 ml) for
10 min at 30°C and centrifuged, and the beads were loaded onto an SDS-PAGE
(12% polyacrylamide) gel. After electrophoresis, the gel was dried and exposed
to X-ray film.
EMSAs. EMSAs were performed as previously described (19). The synthetic
double-stranded oligonucleotide used in the binding reactions was 59-end labeled
with 32P by using the Klenow reaction. The ZII double-stranded oligonucleotide
consists of the single-stranded oligonucleotides 59 AGCTTCCATGACATCAC
AGAGGAGGCTGGGATC 39 and 59 GATCCCAGCCTCCTCTGTGATGTC
ATGGAAGCT 39. The binding reactions were conducted in a buffer consisting
of 60 mM potassium chloride, 12 mM HEPES (pH 7.9), 4 mM Tris-HCl (pH 7.9),
10% glycerol, 1 mM EDTA, and 1 mM DTT, with 4 mg of poly(dI-dC)–poly(dI-
dC) (Pharmacia). Twenty micrograms of B95-8 cell extract was added, and the
mixture was incubated at room temperature for 10 min prior to the addition of
labeled probe (20,000 cpm). For supershifts, the protein extract was incubated
with 3 mg of each antibody (ATF1, ATF2, CREB, or c-Jun from Santa Cruz) for
45 min prior to the binding reaction. The sequences of the competitors are as
follows: SP1, 59-ATTCGATCGGGGCGGGGCGAGC-39 and 39-TAAGCTAG
FIG. 3. CREB, ATF1, ATF2, and c-Jun activate the Z promoter. (A) DG75
cells were transfected with 5 mg of ZpBS-CAT and 1 mg of transactivator plasmid
(vector alone, CREB, ATF1, ATF2, or c-Jun), along with 1 mg of the appropriate
kinase expression vectors to activate each transactivator (PKA for CREB and
ATF1; p38, JNK, and cdc42 for ATF2; and JNK and cdc42 for c-Jun). (B) DG75
cells were transfected with 5 mg of 2221 ZpZIIm-CAT and 1 mg of transactivator
plasmid (vector alone, CREB, ATF1, ATF2, or c-Jun), along with 1 mg of the
appropriate kinase expression vectors to activate each transactivator (PKA for
CREB and ATF1; p38, JNK, and cdc42 for ATF2; and JNK and cdc42 for c-Jun).
(C) DG75 cells were transfected with 5 mg of ZpBS-CAT, along with either 1 mg
of transactivator plasmid (vector alone, ATF2 or c-Jun), 1 mg of kinase (p38 or
JNK and cdc42), or a combination of these plasmids as indicated. CAT assays
were performed as described. The average fold activation (and range), relative to
vector alone, is presented.
1226 ADAMSON ET AL. J. VIROL.
CCCCGCCCCGCTCG-59; and CREB, 59-AGAGATTGCCTGACGTCAGAG
AGCTAG-39 and 39-TCTCTAACGGACTGCAGTCTCTCGATC-59. Each
competitor was used at 200-fold excess over the probe. After addition of the
probe, the reaction mixtures were incubated for 30 min at room temperature and
then loaded onto a 4% polyacrylamide gel and run in 13 Tris-glycine-EDTA
(TGE) at room temperature.
FACS analysis. Anti-IgG-treated Akata cells (100 mg of antihuman IgG per ml
[Sigma] for 4 h), in the absence or presence of 10 mM p38 inhibitor SB 202190
(Calbiochem), were washed twice with PBS, fixed with 60% acetone for 10 min
on ice, washed three times with PBS–0.5% BSA and incubated with a 1:100
dilution of the primary antibody (BMRF1 [Capricorn], Z [Argene], or R [Ar-
gene]) for 1 h at room temperature. The cells were washed three times and then
incubated in the secondary antibody (GAM fluorescein isothiocyanate [1:100],
from Sigma) for 1 h at room temperature. The cells were washed three times and
resuspended in 0.5 ml of PBS. The percentage of immunofluorescent cells was
determined with a FACS machine (Becton Dickinson).
RESULTS
The ZII element is an important component for R-mediated
activation of the Z promoter. Although the R protein has been
previously shown to activate the Z promoter (80), there are no
known R-binding sites in the Z promoter. The Z promoter
contains an upstream regulatory element, referred to as ZII,
that has been previously shown to be an important positive
regulator of Z transcription (10, 14, 16, 65). To examine
whether the ZII element plays a role in R activation of Z
expression, we examined the effect of R on Z promoter activity
by using Z promoter constructs that contain either a wild-type
(2221 Zp-CAT) or mutant (2221 ZpZIIm-CAT) ZII element,
in DG75 (EBV-negative) and Raji (EBV-positive) cell lines
(Fig. 1). In both cell lines, R activation of the wild-type pro-
moter was significantly higher than activation of the promoter
containing a mutant ZII site. Therefore the ZII element plays
a major role in R activation of the Z promoter.
The ZII element of the Z promoter binds ATF1, ATF2,
CREB, and c-Jun. ZII was originally identified as an AP1 site
(16), but has since been shown to be a CRE site (4, 49, 76). We
performed EMSAs with an oligonucleotide probe spanning the
ZII element and B95-8 cell extracts. As shown in Fig. 2 (left
panel), a CRE competitor oligonucleotide competed the top
two binding complexes (labeled A and B), while a control
competitor oligonucleotide (Sp1) did not. An anti-ATF1 anti-
body supershifted protein, although it is difficult to determine
which complex is being supershifted. Anti-ATF2 and anti-c-
Jun antibodies both supershifted proteins from the upper CRE
complex (left panel), while an anti-CREB antibody blocked
formation of the lower CRE complex (right panel). These
results suggest that the A complex contains predominantly
ATF2 and c-Jun, while the B complex contains predominantly
CREB (and possibly ATF1). The finding that ATF1, ATF2,
CREB, and c-Jun bind to the ZII element has recently been
obtained by two other laboratories (14, 49, 76).
FIG. 4. Z and R increase phosphorylation of ATF2. HeLa cells were infected with adenovirus (Ad)-LacZ, adenovirus-Z, or adenovirus-R as indicated. Immunoblot
analysis was performed with antibodies directed against total ATF2 and phosphorylated ATF2 (A) or total CREB and phosphorylated CREB/ATF1 (B). Both
phosphorylated CREB and phosphorylated ATF1 are recognized by a single antibody. At least two separate experiments are presented for each antibody. Infection
of cells with adenovirus-LacZ did not affect ATF2, ATF1, or CREB phosphorylation in comparison to levels in mock-infected cells (data not shown).
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CREB, ATF1, ATF2, and c-Jun activate the Z promoter. The
ZII regulatory element is a positive regulator of the Z pro-
moter, suggesting that factors which bind to ZII may activate
the Z promoter. To examine whether CREB, ATF1, ATF2, or
c-Jun is able to activate Zp, we cotransfected a Z promoter
construct (linked to the CAT gene) with expression vectors for
either CREB, ATF1, ATF2, or c-Jun, plus the kinases known
to activate each of these transcription factors (Fig. 3A). CREB,
ATF1, ATF2, and c-Jun each activate the intact Z promoter in
the presence of the appropriate kinases. Similar results were
previously obtained for the ATF1/CREB factors (14, 76); this
is the first demonstration that phosphorylated ATF2 also ac-
tivates the Z promoter. While the ATF2 and c-Jun transcrip-
tion factors require the ZII motif for activation of the Z pro-
moter, CREB and ATF1 both retained the ability to activate
the mutant Z promoter construct. Therefore, CREB and
ATF1 may also activate the Z promoter through motifs other
than ZII. To confirm that efficient ATF2 and c-Jun activation
of the Z promoter requires p38 kinase and/or JNK, we com-
pared the effect of ATF2 and c-Jun with or without p38 kinase
or JNK (Fig. 3C). As expected, maximal activation of the Z
promoter required cotransfection with both a transactivator
(ATF2 or c-Jun) and a kinase. JNK and p38 kinase alone,
however, also induced some activation of the Z promoter,
likely reflecting the ability of these kinases to activate endog-
enous ATF2 and c-Jun.
Z and R increase the level of phosphorylated ATF2. Since
CREB, ATF1, ATF2, and c-Jun activate the Z promoter, we
examined whether the expression of Z or R affects Z transcrip-
tion by altering the levels of protein binding to ZII. Electro-
mobility gel shift assays were performed with a ZII probe and
extracts of HeLa cells infected with adenovirus-LacZ, adeno-
virus-Z, or adenovirus-R (data not shown). The expression of
either Z or R in the HeLa cells had a minimal effect upon the
level of protein binding to ZII. Therefore, neither Z nor R
activates the Z promoter by increasing the levels of cellular
transactivators binding to the ZII element.
The CREB, ATF1, and ATF2 transcription factors require
phosphorylation by PKA (CREB and ATF1), p38 (ATF2), or
JNK (c-Jun and ATF2) for efficient transactivation function.
Therefore, we examined whether Z or R increases the levels of
phosphorylated ATF2, CREB, or ATF1. In extracts of HeLa
cells that had been infected with adenovirus-LacZ, adenovi-
rus-Z, or adenovirus-R (Fig. 4A), total ATF2 levels were un-
changed after expression of either Z or R. In the same extracts,
however, by using an antibody that specifically recognizes only
the transcriptionally active (phosphorylated) form of ATF2,
both Z and R were found to significantly increase the phos-
phorylation of ATF2. In contrast, R and Z did not consistently
alter the levels of phosphorylated CREB or phosphorylated
ATF1 (Fig. 4B).
Z activates ATF2 and c-Jun transactivator functions in re-
porter gene assays. The finding that adenovirus-Z and adeno-
virus-R infections induce the activity of ATF2 by phosphory-
lation suggests that Z and R could indirectly activate the ZII
site by inducing the transcriptional function of ATF2. We
examined the ability of the CREB, ATF1, ATF2, and c-Jun
proteins (fused to the yeast GAL4 DNA-binding domain) to
activate a reporter construct containing five copies of the
GAL4 DNA-binding site upstream of the adenovirus E1B
TATA box, in the presence or absence of Z (Fig. 5A). Al-
though Z clearly enhanced the transcriptional activator func-
tion of ATF2 and c-Jun, Z did not increase ATF1 transactiva-
tor function and decreased CREB transactivator function.
Thus, Z primarily activates ATF2 and c-Jun (rather than ATF1
or CREB) transactivation function. These reporter gene assays
also confirm that Z-mediated activation of ATF2 is not depen-
dent upon any adenovirus-encoded proteins. We were unable
to perform similar reporter gene assays with R, since R acti-
vated the GAL4-E1B-CAT reporter construct alone (in the
absence of transactivators) to a high level (data not shown).
To examine the domains of Z required for activation of
ATF2 transcriptional function, a series of Z mutants (Fig. 5B)
were cotransfected with GAL4-ATF2 and the GAL4-E1B-
CAT reporter. As shown in Fig. 5C, both the transactivation
domain (Z-CT) and the leucine zipper dimerization domain
(ZDLZ) of Z are required to activate ATF2. A mutation within
the DNA binding domain of Z (Z311), which renders the
protein unable to bind directly to Z-response elements or AP1
motifs, still activates ATF2 to some extent.
FIG. 5. Z activates ATF2 and c-Jun transactivator functions. (A) DG75 cells
were transfected with 5 mg of GAL4-E1B-CAT reporter construct and 1 mg of
SG424 (GAL4 DNA-binding domain alone), GAL4-ATF1, GAL4-ATF2,
GAL4-CREB, or GAL4-c-Jun, with or without the Z expression vector. CAT
assays were performed as described in the text. The average fold activation (and
range) relative to SG424 alone is presented. (B) Construction of Z deletion
mutants. The location of the Z transactivator (TA) and DNA binding (DNA)
and dimerization (DIM) domains is indicated. The Z311 construct is mutated at
amino acid (a.a.) 185 (alanine to lysine) in the Z DNA binding domain and is
defective in DNA binding. (C) DG75 cells were transfected with 5 mg of GAL4-
E1B-CAT reporter construct, 1 mg of GAL4-ATF2, and 1 mg of either control
vector, Z, Z311, Z-CT, or ZDLZ expression vectors. The ATF2 activation in-
duced by each Z construct (relative to the activation induced by wild-type Z, set
at 100%) is shown.
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Z and R increase the activity of p38 and Jun kinases. Acti-
vation of ATF2 transcription function results from phosphor-
ylation at Ser 69/71 by either p38 kinase or c-Jun–N-terminal
kinase (JNK) (26, 58, 75). Since Z and R each increase the
level of phosphorylated ATF2, we investigated whether Z and
R increase the activities of p38 kinase and/or JNK. Extracts of
HeLa cells that had been infected with adenovirus-LacZ, ad-
enovirus-Z, or adenovirus-R were examined for activation of
p38 kinase and JNK. p38 kinase activity was examined by
immunoblot analysis with an antibody which specifically rec-
ognizes the active (phosphorylated) form of p38 kinase, or an
antibody which recognizes both inactive and active (total)
forms of p38 kinase (Fig. 6A). Although neither Z nor R
expression increased the level of total p38 protein, Z and R
both increased the level of phosphorylated p38. The level of
active JNK was quantitated by comparing the phosphorylation
of a GST versus a GST–c-Jun fusion protein (containing the
amino-terminal region of c-Jun that is known to be phosphor-
ylated by JNK), as described in Materials and Methods (Fig.
6B). R and Z both significantly increased JNK activity. Taken
together, these results indicate that both R and Z activate
ATF2 transactivator function by increasing the levels of active
forms of p38 kinase and JNK.
We considered the possibility that Z and R activation of the
stress MAP kinases could be due to an irrelevant stress re-
sponse induced by nonphysiologic overexpression of these pro-
teins. However, by using immunofluorescence (FACS analysis)
to quantitate the level of Z and R expression in the adenovirus-
infected HeLa cells versus that in TPA-induced B95-8 cells, we
found similar levels of cellular Z and R expression (data not
shown). Thus, the levels of Z and R produced in HeLa cells
infected by the Z and R adenoviruses are comparable to phys-
iological levels of Z and R produced by the endogenous EBV
genome.
The disruption of EBV viral latency by R is prevented by
inhibitors of p38 kinase or JNK. JNK is activated by phos-
phorylation via SKK1/SKK4, while p38 kinase is activated
(phosphorylated) by either SKK1/SKK4 or MKK3/MKK6 (11,
43, 64a). To determine which signal transduction pathway (p38
versus JNK) is important for the Z and R effects and whether
activation of the stress MAP kinases is required for disruption
of viral latency, we examined the ability of the R and Z ade-
novirus vectors to induce expression of an early lytic EBV
gene, BMRF1, in NPC-KT (EBV-positive) cells in the absence
or presence of the p38 inhibitor SB 202190 or JIP-1 (which
inhibits JNK activity) (12). The specificities of these inhibitors
are shown in Fig. 7A. SB 202190, which predominantly inhibits
p38 kinase activity, significantly reduced the level of BMRF1
produced by adenovirus-R infection, while not affecting the
level of BMRF1 produced by adenovirus-Z infection (Fig. 7B).
The level of Z produced by adenovirus-R infection was also
reduced by the p38 inhibitor, although the level of R in the
adenovirus-R-infected cells was not affected. These data sug-
gest that p38 kinase activation is important for the disruption
of viral latency by R and, more specifically, for the ability of R
to induce Z expression. Similarly, overexpression of the scaf-
folding JIP-1 protein (which inhibits JNK activity) also pre-
vented the disruption of latency by R, but did not affect the
ability of Z to disrupt latency (Fig. 7C).
To examine the effects of inhibition of upstream activators
of p38 kinase, we transfected D98/HE-R-1 (EBV-positive)
cells with expression plasmids for Z or R, with or without
expression plasmids for dominant-negative forms of MKK3
and MKK6. As expected, both the MKK3 and MKK6 domi-
nant-negatives inhibited phosphorylation of p38 (Fig. 7D).
However, inhibition of MKK3 and MKK6 activities had little
effect upon induction of BMRF1 expression by Z or R (Fig.
7E). Therefore, R activation of p38 kinase is unlikely to be
mediated through MKK3 or MKK6. Taken together, these
results suggest that activation of both JNK and p38 kinase is
required for R-induced disruption of viral latency.
p38 kinase activation is also necessary for efficient disrup-
tion of viral latency by surface Ig cross-linking. To determine
if p38 kinase is important for the disruption of latency induced
by surface Ig cross-linking, we induced Akata cells with anti-
IgG either in the absence or presence of the p38 kinase inhib-
itor SB 202190. We examined expression of BZLF1 and
BMRF1 by immunofluorescence (FACS analysis) (Fig. 8). In
the presence of the p38 kinase inhibitor, the number of cells
expressing BZLF1 or BMRF1 after anti-IgG induction was
significantly decreased. Therefore, p38 kinase activation is also
necessary to efficiently disrupt EBV viral latency from the
endogenous viral genome in B cells by surface Ig cross-linking.
DISCUSSION
The EBV immediate-early proteins Z and R are important
regulatory factors which together initiate lytic replication. Dis-
ruption of viral latency requires transcriptional activation of
the Z and R promoters, and the ability of Z and R to activate
FIG. 6. Z and R increase the levels of activated p38 kinase and JNK. (A) HeLa cells were infected with adenovirus (Ad)-LacZ, adenovirus-Z, or adenovirus-R as
indicated. Immunoblot analysis was performed with antibodies directed against either total p38 or phosphorylated p38. The results from two separate experiments are
presented. (B) Kinase assays were performed as described in the text with extracts from mock-, adenovirus-LacZ-, adenovirus-Z-, or adenovirus-R-infected HeLa cells.
The negative and positive controls are extracts from HEL cells that were either UV irradiated (positive) or unirradiated (negative). Similar results were obtained in
a second experiment (data not shown). Infection of cells with adenovirus-LacZ did not affect p38 kinase or JNK phosphorylation in comparison to levels in
mock-infected cells (data not shown).
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one another’s transcription appears to be a crucial aspect of
this process (1, 80). Z activates the R promoter by a direct
binding mechanism (1, 66). Our results here indicate that R
activates Z transcription indirectly, by activating p38 kinase
and JNK, thereby inducing phosphorylation of transcription
factors (ATF2 and c-Jun) which bind to the ZII element of the
Z promoter. Interestingly, members of the MEF2 transcription
factor family, which bind to and activate the Z promoter
through ZI motifs (3, 50), have also recently been shown to be
phosphorylated (and at least in some cases activated) by p38
kinase (54, 78). Therefore, R-induced activation of p38 kinase
and JNK could potentially induce BZLF1 transcription by a
combined effect on several different transcription factors
(ATF2, c-Jun, and MEF2) involving binding to both the ZI and
ZII binding motifs. The finding that p38 kinase activation is
required for efficient disruption of EBV latency by surface Ig
cross-linking suggests that this pathway plays an important role
in regulating the stringency of viral latency in vivo.
The ZII element is bound by CREB, ATF1, and an ATF2/
c-Jun heterodimer. Potentially, phosphorylation of any one of
these ZII-binding factors might be sufficient to activate the Z
promoter, given our finding that each of these transcription
factors activates the Z promoter in the presence of the appro-
priate activated kinase. Although it is possible that some stim-
uli (such as coinfection with HHV-6) induce lytic EBV infec-
tion through activation of CREB or ATF1, the effects of both
R and Z on ZII-mediated transcription appear to be mediated
through activation ATF-2 and c-Jun.
R and Z increase ATF2 phosphorylation through at least
two different mechanisms. R and Z clearly increase the level of
active (phosphorylated) p38 kinase, which is known to phos-
phorylate (and activate) ATF2. In addition, R and Z also
induce JNK activity, which phosphorylates ATF2 at the same
sites as p38 (26). Z activation of ATF2 requires the Z trans-
activation and leucine zipper domains of Z, but does not re-
quire Z DNA-binding activity. Therefore, Z likely modulates
the p38 and JNK kinase pathways through protein-protein
interactions. We have not yet defined the regions of R required
for ATF2 phosphorylation.
Our finding that both of the EBV immediate-early proteins
activate the stress MAP kinases suggests that activation of
these kinases is important for efficient lytic EBV infection.
Interestingly, another EBV protein, LMP-1, has also recently
been shown to activate the JNK pathway (13, 38). The results
from the p38 and JNK inhibitor studies suggest that R must
activate both JNK and p38 kinase to disrupt viral latency in
epithelial cells. The finding that efficient induction of lytic EBV
FIG. 7. p38 kinase and JNK are necessary for R to disrupt EBV viral latency.
(A) DG75 cells were transfected with 5 mg of GAL4-E1B-CAT reporter con-
struct, and 1 mg of SG424 or GAL4-ATF2, along with 1 mg of p38 or JNK
expression plasmids, with or without the p38 inhibitor SB 202190 (10 mM) or 2
mg of JIP-1 expression plasmid. CAT assays were performed as described in the
text. The ATF2 activation induced (relative to the activation induced by JNK
alone or p38 kinase alone, set at 100%) is shown. (B) NPC-KT cells were infected
with adenovirus-R or adenovirus-Z in the absence or presence of the p38 kinase
inhibitor SB 202190 (10 mM). Immunoblot analysis was performed with antibod-
ies directed against BMRF1, Z or R. Longer exposures indicated that the p38
inhibitor did not affect the level of R protein induced by adenovirus-Z. (C)
D98/HE-R-1 cells were transfected with vector alone, R, Z, R plus JIP-1, or Z
plus JIP-1 as indicated. Immunoblot analysis was performed with antibodies
directed against BMRF1, R, or Z. (D) NIH 3T3 cells were transfected with p38
kinase or a combination of p38 kinase and the dominant-negative MKK3 or
MKK6 expression plasmids (dnMKK3 or dnMKK6). Immunoblot analysis was
performed with antibodies directed against phosphorylated p38 or total p38. (E)
D98/HE-R-1 cells were transfected with vector alone, R, Z, R plus dnMKK3/
dnMKK6, or Z plus dnMKK3/dnMKK6 as indicated. Immunoblot analysis was
performed with antibodies directed against BMRF1.
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infection through activation of the B-cell receptor (cross-link-
ing of surface Ig) likewise requires p38 kinase activation sug-
gests that this pathway is important for lytic EBV infection in
B cells, as well.
However, even in the presence of the p38 kinase inhibitor,
cross-linking of Ig produced some induction of lytic EBV in-
fection (although greatly reduced). The residual induction of
lytic EBV infection which occurs even in the absence of acti-
vated p38 kinase could be mediated through activated JNK.
Alternatively, activation of the R promoter alone, since it di-
rects transcription of a bicistronic R-Z message (53), is poten-
tially sufficient to disrupt viral latency, albeit less efficiently.
Although both R and Z activate ATF-2 and c-Jun phosphor-
ylation, only R has been shown to activate Z transcription from
the endogenous EBV genome when transfected into latently
infected cells (40, 44, 80). The inability of transfected Z to
induce BZLF1 transcription from the endogenous viral ge-
nome may reflect the recent finding that Z interacts directly
with CBP (CREB-binding protein) (2, 81). CREB transactiva-
tor function requires not only phosphorylation at amino acid
133, but also a direct interaction between CREB and CBP (6,
41). The amount of CBP in cells is limiting, and we have
recently shown that Z inhibits CREB transcriptional function
by competing for available CBP (2).
The ATF2 and c-Jun proteins also require direct interaction
with CBP and/or p300 for optimal transactivator function (32,
33). Therefore, Z regulation of its own transcription likely
reflects the balance between Z-induced stimulation (mediated
through phosphorylation of ATF-2 and c-Jun, and possibly by
direct Z binding to upstream ZRE sites [17]), versus Z-induced
inhibition (mediated through competition for limiting amounts
of cellular CBP). The overall effect of Z on its own transcrip-
tion is likely dependent upon the availability of CBP and the
amount of Z. We propose a model in which very low levels of
Z protein initially activate BZLF1 transcription through phos-
phorylation of ATF-2 and/or c-Jun, but, as higher levels of Z
protein accumulate, Z shuts down its own transcription
through competition for limiting amounts of CBP and/or p300.
In any event, the requirement for Z to stimulate its own tran-
scription is clearly bypassed when Z is transfected into cells
under the control of a strong heterologous promoter, and the
predominant effect of such vectors instead may be competition
for limiting amounts of CBP and/or p300 by Z.
A number of different types of cellular stresses (UV irradi-
ation, osmotic shock, inflammatory cytokines, and growth fac-
tors, among others) induce activation of the cellular stress
MAP kinases (7, 52, 72). Induction of the stress MAP kinase
cascade has a multitude of phenotypic effects (including either
induction of, or protection from, apoptosis), depending upon
the cell type and circumstances. Activation of the stress MAP
kinase cascade may be a common response of cells to infection
by viruses, as well. Interestingly, in addition to our findings
with EBV, CMV infection has been shown to activate p38
kinase (31), and HSV-1 infection has been shown to activate
p38 kinase and JNK (55, 79), and activation of at least one of
these kinases is likewise required for efficient lytic viral repli-
cation by both of these viruses. It is quite remarkable that three
different herpesviruses (herpes simplex virus type 1, CMV, and
EBV) take advantage of (and in fact, amplify) a normally
protective response to cellular stress and use it to induce rep-
lication of their own genomes. Inhibition of p38 kinase and/or
JNK activities may therefore prove to be an effective mecha-
nism for preventing viral replication of a variety of herpesvi-
ruses.
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